American college of rheumatology and transcatheter cardiovascular therapeutics

摘要

The main reason patients with rheumatoid arthritis switch from an anti-tumor necrosis factor (TNF) agent to the Janus kinase QAK) inhibitor tofacitinib (Xeljanz, Pfizer), said Dr. Genovese, "is to get away from an injectable drug to an oral one—or it might be related to inadequacy of clinical response from the TNF-inhibitor." Dr. Genovese led a phase 3 trial in which patients liad received oral tofacitinib or subcutaneous (SC) injections of adali-mumab (Humira, Abb Vie), both on top of methotrexate. The patients (n = 124) were then moved directly from the phase 3 randomized, placebo-controlled ORAL trial to an open-label extension without a washout period.